High frequency of voriconazole-related phototoxicity in cystic fibrosis patients

European Respiratory Journal

Volumn 39, Issue 3, 2012, Pages 782-784

  Rondeau, S ^a   Couderc, L ^a   Dominique, S ^a   Pramil, S ^a   Leguillon, C ^a   Masseline, B ^a   Favennec, L ^a   Marguet, C ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; VORICONAZOLE;

AGE DISTRIBUTION; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FACE RASH; GENOTYPE; HUMAN; LETTER; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; PHOTOTOXICITY; PRIORITY JOURNAL; RASH; SEASONAL VARIATION; SEX DIFFERENCE; SKIN EXFOLIATION; SUNBURN; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DERMATITIS, PHOTOTOXIC; FEMALE; HUMANS; MALE; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; TRIAZOLES; YOUNG ADULT;

EID: 84860331468     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00097611     Document Type: Letter

References (13)

1. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637. (Pubitemid 36259570)
2. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4: 215-220. (Pubitemid 43013027)
3. Rubenstein M, Levy ML, Metry D. Voriconazole-induced retinoid-like photosensitivity in children. Pediatr Dermatol 2004; 21: 675-678. (Pubitemid 39657395)
4. Pfizer Canada. Voriconazole Product Monograph. www.pfizer.ca/en/our- products/products/monograph/140 Date last updated: August, 4: 2010.
5. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571. (Pubitemid 34165316)
6. Berge M, Guillemain R, Tregouet DA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011; 67: 253-260.
7. Cheng MP, Paquette K, Lands LC, et al. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients? Pediatr Pulmonol 2010; 45: 661-666.
8. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172. (Pubitemid 38691615)
9. Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26: 648-653. (Pubitemid 33070418)
10. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1995; 39: 793.
11. Tamura A, An R, Hagiya Y, et al. Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems. Expert Opin Drug Metab Toxicol 2008; 4: 255-272. (Pubitemid 351618772)
12. Agrawal N, Ray RS, Farooq M, et al. Photosensitizing potential of ciprofloxacin at ambient level of UV radiation. Photochem Photobiol 2007; 83: 1226-1236. (Pubitemid 47438522)
13. McCarthy KL, Playford EG, Looke DF, et al. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44: e55-e56. 785